Evidence map›Paper›PMID 29550030›Full record

ReviewLancet (London, England)2018

Delivering modern, high-quality, affordable pathology and laboratory medicine to low-income and middle-income countries: a call to action.

Susan Horton, Richard Sullivan, John Flanigan, Kenneth A Fleming, Modupe A Kuti, Lai Meng Looi, Sanjay A Pai, Mark Lawler

Abstract readReview
PubMed Publisher
In one paragraph

Review in Lancet (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Laboratory diagnosis of melioidosis.PLoS neglected tropical diseases · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Susan HortonSchool of Public Health and Health Systems, University of Waterloo, Waterloo, ON, Canada. Electronic address: sehorton@uwaterloo.ca.
Richard SullivanInstitute of Cancer Policy, King's College, London, UK.
John FlaniganCenter for Global Health, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kenneth A FlemingCenter for Global Health, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Green Templeton College, University of Oxford, Oxford, UK.
Modupe A KutiDepartment of Chemical Pathology, College of Medicine, University of Ibadan, and University Hospital, Ibadan, Nigeria.
Lai Meng LooiDepartment of Pathology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Sanjay A PaiColumbia Asia Referral Hospital, Bangalore, India.
Mark LawlerFaculty of Medicine, Health and Life Sciences and Centre for Cancer Research and Cell Biology, Queens University, Belfast, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Modern, affordable pathology and laboratory medicine (PALM) systems are essential to achieve the 2030 Sustainable Development Goals for health in low-income and middle-income countries (LMICs). In this last in a Series of three papers about PALM in LMICs, we discuss the policy environment and emphasise three crucial high-level actions that are needed to deliver universal health coverage. First, nations need national strategic laboratory plans; second, these plans require adequate financing for implementation; and last, pathologists themselves need to take on leadership roles to advocate for the centrality of PALM to achieve the Sustainable Development Goals for health. The national strategic laboratory plan should deliver a tiered, networked laboratory system as a central element. Appropriate financing should be provided, at a level of at least 4% of health expenditure. Financing of new technologies such as molecular diagnostics is challenging for LMICs, even though many of these tests are cost-effective. Point-of-care testing can substantially reduce test-reporting time, but this benefit must be balanced with higher costs. Our research analysis highlights a considerable deficiency in advocacy for PALM; pathologists have been invisible in national and international health discourse and leadership. Embedding PALM in LMICs can only be achieved if pathologists advocate for these services, and undertake leadership roles, both nationally and internationally. We articulate eight key recommendations to address the current barriers identified in this Series and issue a call to action for all stakeholders to come together in a global alliance to ensure the effective provision of PALM services in resource-limited settings.

Indexed as

Clinical Laboratory ServicesDeveloping CountriesHealth EducationHealth ExpendituresHealth PolicyHealth Services Needs and DemandHumansPathologistsPoint-of-Care SystemsPovertyPublic HealthQuality of Health Care

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.